While serving as Senior vice president and chief compliance officer of Amgen Inc., Anna Richo was responsible for the global pharmaceutical company’s compliance and business ethics programs. Anna Richo reported on environmental sustainability efforts for Amgen. An international biotechnology leader, Amgen continues to remain focused on using resources wisely and operating in an environmentally responsible manner. Amgen is committed to improved efficiency in research, in development of medicines, and in processes of manufacturing. Known for its innovative building policies, Amgen plans, constructs, and operates its facilities with a conservation mindset. Amgen sites around the world are evidence of this environmentally responsible construction. In Singapore, a state-of-the-art biomanufacturing plant has been built that will drastically reduce water use, solid waste output, and carbon emissions. Amgen’s considerable water conservation efforts in California and Puerto Rico have been stepped up even more in response to drought. Over the past several years, Amgen has increased energy conservation practices, which has largely reduced carbon emissions in the company. Amgen also lists renewable and alternative energy as a part of its long-term plans. This biology-focused company has a deep appreciation for natural resources and is continually looking for new ways to limit its impact on the environment.
0 Comments
An experienced biopharmaceutical professional, Anna Richo oversees legal affairs, intellectual property, and compliance in her role as executive Vice President and general counsel of UCB in Brussels, Belgium. Earlier in her career, Anna Richo served as senior vice president and chief compliance officer of Amgen, Inc. In early June 2016, Amgen announced the results of its most recent Phase 2 clinical study that tested the effectiveness of an innovative new pharmaceutical. Called erenumab (or AMG 334), this drug focuses on the body’s Calcitonin-Gene-Related-Peptide (CGRP) receptor and prevents it from sending migraine pain signals to the brain. Amgen tested erenumab over the course of 12 weeks, analyzing 667 participants who were afflicted with up to 18 migraines each month. At the beginning of the clinical trial, the trial aimed to decrease the number of days on which patients experienced migraines, particularly within the last month of testing. To best determine erenumab’s effects, Amgen designed a study that randomized the participants, subcutaneously administering a placebo to some of them while others received one of two dose strengths of erenumab. The results were promising, as those who received doses of erenumab saw a migraine reduction of 6.6 days per month. Patients who received the placebo only experienced a 4.2-day-per-month decline. On the back of these results, Amgen will soon pursue Phase 3 studies and present erenumab to the medical community at an upcoming conference. |
AuthorAs of November 1, 2012, Anna Richo became Executive Vice President and General Counsel of UCB, a biopharmaceutical company headquartered in Brussels, Belgium. Archives
August 2018
Categories
All
|